Narrative
PathXL Ltd is a global digital pathology software company, founded by Queen’s researchers who successfully commercialised a novel technology for objective evaluation of performance in cancer diagnostics and thereby improved cancer pathology training. The company’s products initially revolutionized the professional training of young pathologists in the UK and Australia. Now products extend to software for tissue biomarker development, precision medicine and biobanking. PathXL Ltd has raised significant venture capital funding to expand its business growing from 2 to 30 people and is now selling a range of world leading digital pathology products for education, biopharmaceutical and diagnostic research and clinical practice across the world.| Impact status | Ongoing |
|---|---|
| Category of impact | Health Impact, Quality of Life Impact |
Related content
-
Research output
-
A computer-based training system for breast fine needle aspiration cytology
Research output: Contribution to journal › Article › peer-review
-
Expert System Support Using A Bayesian Belief Network For The Classification Of Endometrial Hyperplasia
Research output: Contribution to journal › Article › peer-review
-
EXPERT-SYSTEM SUPPORT USING BAYESIAN BELIEF NETWORKS IN THE DIAGNOSIS OF FINE-NEEDLE ASPIRATION BIOPSY SPECIMENS OF THE BREAST
Research output: Contribution to journal › Article › peer-review
-
IMPROVED DIAGNOSTIC DECISION-MAKING IN PATHOLOGY - DO INFERENCE NETWORKS HOLD THE KEY
Research output: Contribution to journal › Editorial › peer-review
-
PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) - PERFORMANCE OF BAYESIAN BELIEF NETWORK FOR DIAGNOSIS AND GRADING
Research output: Contribution to journal › Article › peer-review
-
Ultra-fast processing of gigapixel Tissue MicroArray images using high performance computing.
Research output: Contribution to journal › Article › peer-review